GSK Plans to Close Facility in Ireland
GSK will close the Sligo, Ireland skincare product manufacturing site by 2021.
GlaxoSmithKline (GSK) informed employees at its skincare product manufacturing site in Sligo, Ireland of a proposal to close the site, the company announced in an Aug. 16, 2018 statement. Under this proposal, which affects approximately 165 employees, the company would phase down production over three years, before decommissioning the site in the latter part of 2021.
Although the Sligo site has delivered significant improvements in cost and efficiency in recent years, demand for the products made at the site has not grown in line with previous expectations, the company explained. GSK’s other operations in Ireland, including manufacturing sites in Cork and Dungarvan and commercial operations in Dublin, are not affected by this proposal.
Source: GSK
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
